Cerivastatin for lowering lipids
Abstract
This is a protocol for a Cochrane Review (Intervention). The objectives are as follows:
Primary objective:
To learn more about the pharmacology of cerivastatin by characterizing the dose‐related effect and variability of the effect of cerivastatin on the surrogate marker: low‐density lipoprotein (LDL cholesterol). The effects of statins on morbidity and mortality is not the objective of this systematic review.
Secondary objectives:
To characterize the dose‐related effect and variability of effect of cerivastatin on the surrogate markers: total cholesterol, high‐density lipoprotein (HDL cholesterol), and triglycerides.
To quantify the effect of various doses of cerivastatin on withdrawals due to adverse effects.